The ubiquitin-proteasome system (UPS) is an important intracellular proteolytic pathway responsible for the degradation of proteins and oxidative damage; hence it plays a central role in maintaining homeostasis of red blood cells (RBCs). The present study investigated the levels of polyubiquitination, the function of proteasomes and effect of hydroxycarbamide (HC) therapy in RBCs from sickle cell disease (SCD) patients. Polyubiquitinated proteins were found to be elevated in untreated SCD (UT-SCD) patients compared to those in HC-treated SCD patients (HC-SCD) and controls. Activities of b1 and b2 subunits were a little higher in UT-SCD patients, and much higher proteolytic activities were observed in all three subunits (b1, b2 and b5) of RBCs in HC-SCD patients compared to those of UT-SCD patients and controls, although the protein levels of these subunits remained approximately the same. It is notable that, despite HC therapy, some patients showed persistent complications and accumulation of polyubiquitinated proteins. The enhanced proteasomal activity among HC-treated patients might remove the polyubiquitinated protein and could be one of the important mechanisms of therapeutic action. These findings could be useful to understand the pathophysiology of SCD and its clinical heterogeneity and identify a suitable therapeutic target for the better management of these patients.
Summary
The ubiquitin-proteasome system (UPS) is an important intracellular proteolytic pathway responsible for the degradation of proteins and oxidative damage; hence it plays a central role in maintaining homeostasis of red blood cells (RBCs) . The present study investigated the levels of polyubiquitination, the function of proteasomes and effect of hydroxycarbamide (HC) therapy in RBCs from sickle cell disease (SCD) patients. Polyubiquitinated proteins were found to be elevated in untreated SCD (UT-SCD) patients compared to those in HC-treated SCD patients (HC-SCD) and controls. Activities of b1 and b2 subunits were a little higher in UT-SCD patients, and much higher proteolytic activities were observed in all three subunits (b1, b2 and b5) of RBCs in HC-SCD patients compared to those of UT-SCD patients and controls, although the protein levels of these subunits remained approximately the same. It is notable that, despite HC therapy, some patients showed persistent complications and accumulation of polyubiquitinated proteins. The enhanced proteasomal activity among HC-treated patients might remove the polyubiquitinated protein and could be one of the important mechanisms of therapeutic action. These findings could be useful to understand the pathophysiology of SCD and its clinical heterogeneity and identify a suitable therapeutic target for the better management of these patients.
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Sickle cell disease (SCD) is one of the most common monogenic disorders with an autosomal recessive inheritance resulting from the missense mutation Glu6Val in the HBB (beta-globin) gene, with the resultant protein designated as sickle haemoglobin (HbS) (Ware et al, 2017) . It is characterized by painful vaso-occlusive crisis, accelerated haemolysis and chronic organ damage. Deoxygenation-induced polymerization of HbS leading to erythrocyte injury, vasoocclusion and extra and intravascular haemolysis is the primary pathology seen in patients with SCD, which subsequently leads to a cascade of pathological events responsible for varied clinical manifestations. Some of the important events include dehydration of red blood cells (RBCs), abnormal adhesion of RBCs to the vascular endothelium, endothelial dysfunction, functional deficiency of nitric oxide (NO), increased oxidative stress and inflammation (Piel et al, 2017) . Varied clinical heterogeneity is observed in patients with SCD despite the identical underlying genetic defect. Apart from well-known genetic factors, such as fetal haemoglobin (HbF) levels and a-thalassaemia, many other genetic and non-genetic factors contribute to this remarkable clinical heterogeneity, although these are not yet clearly understood (Steinberg & Sebastiani, 2012) .
Many studies have previously documented oxidative stress in patients with SCD and its association with various clinical manifestations (Voskou et al, 2015) . Auto-oxidation of HbS in its deoxygenated state is responsible for the generation of reactive oxygen species (ROS). The production of ROS further accelerates haemolysis, endothelial dysfunction, cell adhesion and vaso-occlusion, contributing to the chronic organ damage in SCD patients (Chirico & Pialoux, 2012; Kato et al, 2017) . The released ferric ion from degraded haemoglobin catalyses the production of hydroxyl radical via the Fenton chemistry and thereby triggers the fatal cycle.
The ubiquitin-proteasome system (UPS) is major intracellular proteolytic machinery responsible for the degradation of proteins with structural anomaly and oxidative damage (Shang & Taylor, 2011) . Proteins damaged by oxidative stress experience polyubiquitination and undergo clearance by the proteasome system (Davies, 2001) . The 26S proteasome consists of two subcomplexes; the 20S catalytic core complex and the 19S regulatory complex. The 20S catalytic complex has a cylindrical structure carrying the proteolytic active site in b1, b2 and b5 subunits (Orlowski & Wilk, 2000) . These subunits are associated with caspase-like, trypsin-like and chymotrypsin-like activities, which cleave the peptide bonds at the C-terminal side of acidic, basic and hydrophobic amino acid residues respectively. The 19S regulatory complex serves to recognize ubiquitinated protein and transfer it into the 20S catalytic complex for degradation (Orlowski & Wilk, 2000) .
The UPS is central to the regulation of almost all cellular processes, such as the cell cycle, stress response, signal transduction, and transcriptional regulation to maintain their normal function. The highly regulated UPS affects a wide variety of cellular processes and substrates and defects in this system can result in the pathogenesis of several human diseases (Wag & Maldonado, 2006) . The UPS is also a target of oxidative stress that is caused by elevated ROS and lipid peroxidation products, such as 4-hydroxynonenal, impairing in the function, and leads to accumulation of polyubiquitinated proteins (Shang & Taylor, 2011) . Although earlier studies of proteomic analysis have shown oxidative stress inside the sickle RBCs (Basu et al, 2013) , the role of ubiquitination and proteasomal activity in SCD patients has not been well-studied.
Hydroxycarbamide (HC) is used commonly in the management of SCD and is currently the only approved pharmacological therapy for SCD (Telen, 2016) . Though early diagnosis, antimicrobial prophylaxis, pneumococcal vaccination, safe blood transfusion services and HC therapy have improved the quality of life of these patients, the overall survival of homozygous SCD patients is 58-66 years (Elmariah et al, 2014) . However, clinical manifestations of SCD patients are extremely variable from region to region and within the same geographical area (Colah et al, 2015) . Thus, there is a need for better understanding of the genetic and nongenetic factors contributing to disease pathology and identification of markers to diagnose disease severity and develop comprehensive management strategies for SCD. HC has multiple mechanisms of action including induction of HbF (Cokic et al, 2003) and anti-inflammatory activity (Lanaro et al, 2009) ; however, its effect on UPS system has also not yet been studied.
To date, no systematic study has been undertaken to look for the role of UPS or the mechanisms responsible for how oxidative stress causes the destruction of RBCs due to the accumulation of damaged proteins in SCD. This study was performed to gain insight into the involvement of UPS in SCD pathogenesis and in the therapeutic performance of HC.
Materials and methods

Patients
A total of 44 SCD patients (homozygous Glu4-Val) aged 11-50 years along with 55 healthy controls aged 22-45 years were studied. Of the 44 patients, 27 have been regularly treated with HC for the last 2 years. While 17 are without HC treatment, SCD patients who were transfused in the preceding 3 months were excluded from the study. Blood samples were collected in K2-EDTA tubes after informed consent. Haematological indices were measured on a Sysmex K-1000 automated cell counter (Sysmex, Kobe, Japan). Haemoglobin analysis was done using high performance liquid chromatography on the VARIANT TM Haemoglobin Testing System (Bio-Rad Laboratories, Irvine, CA, USA). The present study was approved by institutional ethics committee of National Institute of Immunohaematology (NIIH), Mumbai, India.
Flow cytometry analyses of reactive oxygen species
RBC suspensions (1 9 10 6 /ml) in phosphate-buffered saline (PBS) were incubated with 2 0 , 7 0 -dichlorofluorescein diacetate (DCFH-DA) (Sigma-Aldrich, St Louis, MO, USA) at a final concentration of 0Á4 mmol/l. After incubation at 37°C for 15 min in a humidified atmosphere of 5% CO 2 , RBCs were washed and re-suspended in PBS. Fluorescence intensity was determined for 10 000 events in the FL-1 channel using a FACSCaliber flow cytometer (Becton Dickinson, San Jose, CA, USA) (Amer et al, 2004) .
Proteasomal activity assays
The proteasomal activities in RBCs were determined by fluorescence assays as described previously (Homma et al, 2015) . Briefly, RBCs collected from subjects were washed three times with PBS and lysed in 20 mmol/l Tris-HCl (pH 7Á5). The lysates were then centrifuged at 25 155 g for 10 min at 4°C. After centrifugation, the supernatant was collected and protein concentrations were determined using Pierce â BCA TM Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). From each RBC sample, 50 lg of total protein was incubated with 200 lmol/l of proteasome substrate z-Leu-Leu-Glu-MCA (for caspase-like activity), Boc-Leu-ArgArg-MCA (for trypsin-like activity) or Suc-Leu-Leu-Val-Tyr-MCA (for chymotrypsin-like activity) in 100 ll assay buffer (20 mmol/l Tris-HCl, pH 7Á5) at 37°C for 60 min. All substrates were procured from Peptide Institute, Inc. (Osaka, Japan). After incubation, the fluorescence intensity was measured using a microplate reader (Varioskan Flash, Thermo
Fisher Scientific) with an excitation filter of 365 nm and an emission filter of 460 nm.
Western blot analyses
Proteins were extracted from RBCs with radioimmunoprecipitation assay buffer, which contains 50 mmol/l Tris-HCl, pH 8Á0, 150 mmol/l NaCl, 1% Nonidet P-40, 0Á5% Deoxycholate and 0Á1% sodium dodecyl sulphate (SDS), supplemented with a protease inhibitor cocktail (Sigma-Aldrich). The lysate was centrifuged at 15 000 rpm for 10 min in a microcentrifuge. After centrifugation, the protein concentration in the supernatants was measured as described above. The proteins were separated on 15% SDS-polyacrylamide gels and blotted onto polyvinylidene difluoride membranes (GE Healthcare, Chicago, IL, USA). The blots were blocked with 5% skimmed milk in Tris-buffered saline containing 0Á1% Tween-20 and then incubated with the antibodies. The primary antibodies used were: Ub (sc-8017; Santa Cruz Biotechnology, Dallas, TX, USA), b1 subunit (BML-PW8140; Enzo Life Sciences, Farmingdale, NY, USA), b2 subunit (BML-PW9300; Enzo Life Sciences), b5 subunit (BML-PW8895; Enzo Life Sciences), and GAPDH (sc-25778; Santa Cruz Biotechnology). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit or anti-mouse IgG antibodies (Santa Cruz Biotechnology) were used as the secondary antibodies. The bands were detected using ImmobilonWestern Chemiluminescent HRP substrate (Millipore, Burlington, MA, USA) on an image analyser (ImageQuant LAS500, GE Healthcare).
Statistical analyses
Statistical analyses were performed using one-way ANOVA followed by the Tukey's post hoc test for multiple groups (PRISM, GraphPad Software Inc., San Diego, CA, USA). A P-value of less than 0Á05 was considered to be significant.
Results
Haematological and biochemical data on SCD patients and control individuals
The haematological and biochemical data on RBCs of SCD patients without (UT-SCD) and with HC treatment (HC-SCD) along with healthy controls are summarized in Table I . SCD patients had increased white blood cell (WBC) counts, reticulocyte counts and total bilirubin levels whereas haemoglobin levels were lower than healthy controls. The haemoglobin level was elevated among HC-SCD patients as compared to UT-SCD patients, indicating improvement in anaemia. The HbF level was significantly higher; while HbS (%) was lower in HC-SCD patients compared to UT-SCD patients.
ROS elevation in RBCs of SCD patients and ROS suppression by HC treatment
Because oxidative stress is reportedly induced in RBCs of the SCD patients (Voskou et al, 2015) , we evaluated ROS levels in RBC by flow cytometry using a ROS-sensitive fluorescent Table I . Haematological and biochemical data of healthy controls and SCD patients.
Parameter
UT-SCD (n = 17) probe, DCFH-DA. The fluorescent intensity of RBC from UT-SCD was more than two-fold higher than the control samples. It was noteworthy that treatment with HC (i.e. in HC-SCD patients) decreased the ROS levels (Fig 1) . Thus, RBC pathological conditions appear to be associated with oxidative stress in SCD.
Proteolytic activities specific to each proteasomal subunit
The proteolytic activities of soluble proteins from RBCs of SCD patients and healthy individuals are shown in Fig 2. The proteolytic activities were found to be significantly higher in all the three subunits (b1, b2 and b5) of RBCs in HC-SCD patients when compared to those of UT-SCD patients and the healthy control group. RBC proteins from patients with persistent complications in-spite of HC therapy did not show such elevation of b1 and b2 subunits as compared to the patients who responded to HC. (Table S1 ).
Elevated polyubiquitinated proteins and their suppression by HC in SCD patients
Polyubiquitinated proteins were found to be more abundant in the RBCs of UT-SCD patients compared to those of HC-SCD patients and healthy controls by Western blot analysis followed by quantification of the positive bands relative to GAPDH bands (Fig 3) . To gain insight into the mechanism for the increased polyubiquitinated protein in UT-SCD, we analysed the protein levels of proteasome catalytic subunits b1, b2 and b5 (Fig 4) . Unexpectedly, HC treatment did not affect the levels of all three catalytic subunits, while the levels of the b2 subunit were even a little higher in the UT-SCD group than in healthy controls. Increased accumulation of polyubiquitinated proteins was observed in two HC-SCD patients (Fig 5) .
Discussion
The present study shows a significant increase in ROS (Fig 1) and polyubiquitinated proteins in the RBCs of SCD patients who were not treated with HC (UT-SCD) compared to healthy controls (Fig 3) . The increase in the accumulation of polyubiquitinated protein in RBCs of UT-SCD patients is likely to be a result of severe oxidative stress caused by HbS. The treatment of SCD patients with HC decreased the polyubiquitinated proteins, which strongly suggests the association of HbS-triggered oxidative stress with the accumulation of polyubiquitinated proteins. Continuous oxidative stress, which impairs the cell signalling pathway and renders cells more susceptible to stress, reportedly inactivates the proteasome function (Wu et al, 2009 ). The overall protein levels of proteasomal catalytic subunits, excluding the slight change in the b2 subunit, were similar between UT-SCD patients and healthy controls. Contrary to the protein levels, the catalytic activities unique to b1 and b2 subunits were slightly higher in the UT-SCD patients, and all three activities were markedly elevated in HC-SCD patients compared to healthy controls and UT-SCD patients (Fig. 2) . Once oxidized, proteins, such as the thirdrichest peroxiredoxin II in RBC, are degraded by the proteasome system without ubiquitination (Cho et al, 2014) . The proteasome is reportedly degraded by autophagy (Waite et al, 2016) , but it is not clear how proteasomal proteins are removed in RBCs that lack the autophagy machinery. It is thus Figure 1 . Levels of reactive oxygen species in RBC from healthy controls and SCD patients. Blood collected from individuals was stained with 2 0 , 7 0 -dichlorofluorescein diacetate, followed by flow cytometry. The relative fluorescent intensity of red blood cells (RBC) is shown, and the number of subjects is shown in parentheses. Data were expressed as the mean AE SE of the mean of RBC. Statistical analysis was performed by one-way ANOVA, followed by the Tukey's test. ***P < 0Á001. AU, arbitrary units; HC-SCD, sickle cell disease patients treated with hydroxycarbamide; UT-SCD, untreated sickle cell disease patients. Figure 2 . The proteasomal activities in RBC from healthy controls and SCD patients. The proteasome activities, including caspase-like, trypsin-like, and chymotrypsin-like activities in red blood cells (RBC)from healthy controls (n = 55), UT-SCD (n = 17), and HC-SCD (n = 25) were monitored. Data were expressed as the mean AE SE of the mean of RBC. Statistical analysis was performed by one-way ANOVA, followed by the Tukey's test. *P < 0Á05, **P < 0Á01, ***P < 0Á001. FU, fluorescence units; HC-SCD, sickle cell disease patients treated with hydroxycarbamide; ns, not significant; UT-SCD, untreated sickle cell disease patients. speculated that proteasomal proteins, even if inactivated by oxidative stress, are persistently present due to lack of their degrading system compared to ordinary nucleated cells. While newly differentiated RBCs possess active proteasome in HC-SCD patients, RBCs from UT-SCD patients may possess more proteasomal proteins in the inactive form than HC-SCD patients. Thus, the elevated catalytic activities of the UPS appear to be involved in the removal of the oxidatively modified proteins via polyubiquitination. Although the mechanism by which HC treatment elevates proteasomal activity remains unknown, these findings may provide a clue to developing novel therapeutic treatments for SCD.
We previously reported that the oxidative stress-induced malfunction in the scavenging activity of proteasomes Quantification of ubiquitinated protein normalized to the corresponding GAPDH by Western blot analyses. The number of subjects is shown in parentheses. Data were expressed as the mean AE SE of the mean of RBC. Statistical analysis was performed by oneway ANOVA, followed by the Tukey's test. *P < 0Á05, ***P < 0Á001. AU, arbitrary units; HC-SCD, sickle cell disease patients treated with hydroxycarbamide; Ub, ubiquitin; UT-SCD, untreated sickle cell disease patients. Data were expressed as the mean AE SE of the mean of RBC (Control, n = 4; UT-SCD, n = 8; HC-SCD, n = 6). Statistical analysis was performed by one-way ANOVA, followed by the Tukey's test. *P < 0Á05. AU, arbitrary units; HC-SCD, sickle cell disease patients treated with hydroxycarbamide; ns, not significant; UT-SCD, untreated sickle cell disease patients.
Dysfunction of the Ubiquitin-Proteasome System in SCD ª 2018 British Society for Haematology and John Wiley & Sons Ltd accelerates the accumulation of damaged proteins, leading to a shortened lifespan of RBCs, and consequently anaemia, in superoxide dismutase 1 (SOD1) deficient mice and phenylhydrazine-induced anaemic mice (Homma et al, 2015) . Therefore, these findings led us to investigate the role of the UPS in human subjects with SCD, in whom the oxidative stress is known to be high. However, the present study implies that elevated ROS due to HbS increases oxidative damage in RBC proteins, which may exceed the proteasome capacity and result in the accumulation of polyubiquitinated proteins in SCD patients (Fig 3) . The inconsistency of the data between our earlier and the present study could be due to the different experimental models.
Accumulation of the polyubiquitinated proteins would cause a defect in RBC homeostasis and accelerate the destruction of RBCs, consequently leading to anaemia and increased disease severity in UT-SCD patients. This notion was further supported by the findings that HC-SCD patients showed decreases in polyubiquitinated proteins but increases in the proteasomal activity. However, earlier studies indicated that HC itself inhibits proteasome activity in human umbilical vein epithelial cells (Cokic et al, 2007) , suggesting that the elevation of the proteolytic activities found in HC-SCD patients was not due to the direct effect of HC on the proteasome of RBCs.
NO is produced from HC via the catalysis of enzymes, such as catalase and peroxidase (Huang et al, 2002 (Huang et al, , 2004 , which are present in relatively high amounts in RBCs. HC appears to be also indirectly involved in NO production by inducing endothelial NO synthase (eNOS) (Cokic et al, 2007) . The resulting NO rapidly reacts with superoxide and is converted to peroxynitrite (Pacher et al, 2007) . Conversely, superoxide is eliminated by NO, which results in suppression of the superoxide-mediated radical chain reaction. Thus, NO-mediated suppression of highly reactive ROS, such as hydroxyl radical, may exert a protective function on the proteasomal activity. While peroxynitrite is a strong oxidant and, in the case of production in large amounts, causes tyrosine nitration and cellular damages (Radi, 2013) , small amounts of peroxynitrite appear to regulate cellular signalling pathways and even activate antioxidative responses (Speckmann et al, 2016) . This notion is supported by the report that ROS induce the 20S proteasome, which is the main proteasome complex in RBCs (Majetschak & Sorell, 2008) , via the NRF2-mediated mechanism (Pickering et al, 2012) . Given that RBCs have no machinery for de novo synthesis of proteins, the NO-mediated reaction of HC may exert a beneficial function on erythroid cells and engage in the production of more 20S proteasomal proteins. Thus, proteasomal activity would be higher in SCD patients who are treated with HC for a certain period of time and participate in the elimination of polyubiquitinated proteins efficiently, leading to the maintenance of RBC homeostasis.
This study also supports earlier findings on HC therapy: HC has an antioxidant capacity and serves as a free radical scavenger to reduce oxidative stress. The increased HbF concentration in HC-SCD patients is associated with less oxidative stress, characterized by decreased lipid peroxidation, and contributes to antioxidant defences (Torres et al, 2012 ). An in-vitro study has shown that HC has anti-oxidant activities against 2, 2-diphenyl-1-picrylhydrazyl (DPPH) and hydroxyl radical (Liu et al, 2010) . Italia et al (2016) have shown that HC reduces levels of ROS, phosphatidylserine, serum ferritin and labile iron pool in patients with beta-thalassaemia intermedia.
The study by Yuditskaya et al (2009) showed that a low level of Apolipoprotein A1 (Apo-A1, APOA1), which is the major protein component of high-density lipoprotein (HDL) in the plasma, is associated with pulmonary arterial hypertension (PAH) in SCD patients. In another study, Anjum et al (2013) showed that the low level of Apo-A1 in SCD patients with PAH is related to UPS dysregulation. Together, these observations imply that dysregulation of the UPS combined with a low Apo-A1 level may contribute to endothelial dysfunction and pulmonary vascular pathology in SCD.
The cellular concentration of proteasomes in RBCs is originally much lower than in nucleated cells, but contains about 10 times more 20S proteasomes than 26S proteasomes (Majetschak & Sorell, 2008) . In addition, the 20S proteasome alone degrades non-ubiquitinated proteins without consuming ATP (Murata et al, 2009) . These imply that elimination of polyubiquitinated proteins is not very efficient in RBC per se, which tends to cause their accumulation, notably under oxidative stress. While NO is involved in the elevation of HbF that mitigates SCD pathogenesis (Cokic et al, 2003) , it may also induce production of proteasomal proteins during erythropoiesis and after maturation, leading to the elimination of both polyubiquitinated proteins and non-ubiquitinated proteins in RBCs.
Interestingly, we have observed that two HC-SCD patients had increased accumulation of polyubiquitination in their RBCs (Fig 5) ; one case had a leg ulcer with avascular necrosis of the femoral head (AVNF) whereas the other case had AVNF and acute chest syndrome associated with severe painful crisis. Both cases had moderate anaemia (Hb: 101 g/l and 104 g/l) and, clinically, had not responded to HC (HbF: 15Á2% and 18Á2%). These findings suggest that polyubiquitinated protein could also be used as a biomarker to evaluate disease progression and the outcomes of SCD patients. This study may also help to explain the clinical heterogeneity or severity of clinical manifestation in SCD patients.
Therefore, we hypothesized that dysregulation of the UPS causes the accumulation of polyubiquitinated protein in UT-SCD patients and is mainly due to the high oxidative stress. However, on HC treatment, proteasomal activity could be increased, further helping to maintain the RBC homeostasis. (Fig 6) To the best of our knowledge, this is the first attempt to investigate the role of the ubiquitin-proteasome system or the mechanism responsible for how oxidative stress can cause the destruction of RBCs from the viewpoint of elimination of oxidatively damaged protein in SCD patients. This finding may help to understand the pathophysiology of SCD and its clinical heterogeneity and could also be useful for identifying suitable therapeutic targets for the better management of patients with SCD.
